HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

LEADS BIOLABS-B

62.000

-1.200-1.90%

Volume:1.11M

Turnover:68.57M

Market Cap:12.34B

PE:-43.87

High:63.300

Open:63.200

Low:61.000

Close:63.200

52wk High:97.500

52wk Low:44.720

Shares:199.00M

HK Float Shares:198.00M

Volume Ratio:0.53

T/O Rate:0.56%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-1.413

ROE:-51.55%

ROA:-12.87%

PB:11.35

PE(LYR):-43.87

PS:49.55

Loading ...

Overview Company News Filings

Nanjing Leads Biolabs Co Ltd: Actively Advancing Relevant Pre-launch Commercialization Preparations

THOMSON REUTERS

Priority Review Granted to Pd-l1/4-1bb Bispecific Antibody Opamtistomig, Accelerating Commercialization and Addressing Unmet Need in Ep-nec

THOMSON REUTERS

Nanjing Leads Biolabs' Cancer Drug Included in China Regulator's Priority Review List

MT Newswires Live

LEADS BIOLABS-B's Novel Cancer Therapy LBL-024 Granted Priority Review in China for Advanced Neuroendocrine Carcinoma

Nanjing Leads Biolabs Says China Regulator Puts Lbl-024 Ep-nec Filing in Priority Review

Leads Biolabs Converts 44.39 Million Unlisted Shares to H Shares, Lifting Outstanding H Shares to 197.67 Million

Bulletin Express

LEADS BIOLABS-B Awards 2.2547 Million Shares Under H-Share Incentive Scheme

Nanjing Leads Biolabs Grants 2,254,691 H-share Awards Under Employee Incentive Scheme

This Nanjing Leads Biolabs Insider Reduced Their Stake By 40%

Simply Wall St.

Assessing LEADS BIOLABS-B After a 50% Price Drop: H-Share Full Circulation, Early Shareholder Unlock, and Custody Movements

New Energy System Blueprint and Rural EV Initiative Unveiled as Key Stocks Report Earnings

Leads Biolabs Announces Partner Oblenio Bio’s $62 Million Oversubscribed Series B Financing to Advance Tri-specific T-cell Engager Lbl‑051 for Autoimmune Diseases into Clinical Development

THOMSON REUTERS

Nanjing Leads Biolabs Co - Series B Round Led by Pfizer Ventures with Deep Track Capital, Gv, and Aditum Bio

THOMSON REUTERS

Nanjing Leads Biolabs Says Partner Oblenio Moves Lbl-051 Toward Clinical Trial Start After US$62 Million Series B Financing

Leads Biolabs Completes H-Share Full Circulation, Free-Float Rises to 99.39%

Bulletin Express

Nanjing Leads Biolabs converts 44,391,598 unlisted shares into H shares for HKEX listing

LEADS BIOLABS-B Records HK$1.486 Billion in Deposited Shares as Major Holder Transfers 25.85 Million Shares

Nanjing Leads Biolabs says LBL-024 Phase II first-line NSCLC data wins oral slot at 2026 WCLC

Leads Biolabs to Spend up to US$50 Million on Trustee-Led H-Share Purchases for Employee Award Scheme

Bulletin Express

LEADS BIOLABS-B (09887) Authorizes Trustee to Acquire Up to $50 Million Worth of H Shares Under Incentive Plan

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/stock/09887/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"09887","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"LEADS BIOLABS-B","latestPrice":62,"timestamp":1789027724007,"preClose":63.2,"halted":0,"volume":1112700,"delay":0,"changeRate":-0.018987341772151944,"floatShares":198000000,"shares":199000000,"eps":-1.4131246275444593,"marketStatus":"Closed","change":-1.2,"latestTime":"09-10 16:08:44","open":63.2,"high":63.3,"low":61,"amount":68573175,"amplitude":0.036392,"askPrice":62,"askSize":2000,"bidPrice":61.95,"bidSize":400,"shortable":3,"etf":0,"ttmEps":-1.6082199129002914,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789090200000},"marketStatusCode":5,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":63.2,"openAndCloseTimeList":[[1789003800000,1789012800000],[1789016400000,1789027200000]],"volumeRatio":0.527291,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","floatShares":198000000,"roa":"-12.87%","roe":"-51.55%","lyrEps":-1.413125,"volumeRatio":0.527291,"shares":199000000,"dividePrice":0,"high":63.3,"amplitude":0.036392,"preClose":63.2,"low":61,"week52Low":44.72,"pbRate":"11.35","psRate":"49.55","week52High":97.5,"institutionHeld":0,"latestPrice":62,"committee":-0.666667,"eps":-1.4131246275444593,"divideRate":0,"volume":1112700,"delay":0,"ttmEps":-1.6082199129002914,"open":63.2,"prevYearClose":51,"prevWeekClose":64,"prevMonthClose":72.3,"prevQuarterClose":49.32,"fiveDayClose":67.7,"twentyDayClose":69.15,"sixtyDayClose":55.25},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09887\",params:#limit:5,,,undefined,":[{"date":"2026-08-31","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1788139800000,"name":null,"time":"","dateTimestamp":1788105600000,"actualEps":null},{"date":"2026-03-27","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774575000000,"name":null,"time":"","dateTimestamp":1774540800000,"actualEps":null},{"date":"2025-08-29","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09887\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09887\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.6667,"hold":0.3333,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":3,"updateTime":1780070400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09887\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09887","date":"2026-09-09","current":-38.501919,"percent":0.554348,"low":-76.458084,"twenty":-45.565149,"median":-39.965338,"eighty":-34.758603,"high":-30.202688,"avg":-42.101948,"sd":9.707299,"marketCap":12331685120},"quantilePoints":[{"date":"2025-07-25","current":-39.760016,"twenty":-39.760016,"median":-39.760016,"eighty":-39.760016,"marketCap":12652000240},{"date":"2025-08-01","current":-42.800562,"twenty":-46.836196,"median":-44.399434,"eighty":-42.800562,"marketCap":13535375000},{"date":"2025-08-08","current":-41.931377,"twenty":-45.734702,"median":-43.894587,"eighty":-42.800562,"marketCap":13293671875},{"date":"2025-08-15","current":-42.360797,"twenty":-44.683717,"median":-42.975881,"eighty":-41.70245,"marketCap":13409689375},{"date":"2025-08-22","current":-41.268557,"twenty":-45.0887,"median":-43.050098,"eighty":-41.70245,"marketCap":13022964375},{"date":"2025-08-29","current":-41.462871,"twenty":-44.683717,"median":-42.745269,"eighty":-41.268557,"marketCap":13146747980},{"date":"2025-09-05","current":-41.718992,"twenty":-44.115151,"median":-41.93996,"eighty":-40.603026,"marketCap":13087080440},{"date":"2025-09-12","current":-41.612383,"twenty":-43.894587,"median":-41.766832,"eighty":-40.253447,"marketCap":13077135850},{"date":"2025-09-19","current":-40.406926,"twenty":-43.894587,"median":-41.814673,"eighty":-40.270938,"marketCap":12689296840},{"date":"2025-09-26","current":-39.940552,"twenty":-43.592616,"median":-41.710721,"eighty":-39.940552,"marketCap":12510294220},{"date":"2025-10-03","current":-46.021818,"twenty":-44.124681,"median":-41.829747,"eighty":-40.190868,"marketCap":14449489270},{"date":"2025-10-10","current":-44.344385,"twenty":-44.480118,"median":-41.935668,"eighty":-40.263942,"marketCap":13902536820},{"date":"2025-10-17","current":-41.267963,"twenty":-44.480118,"median":-42.061577,"eighty":-40.352531,"marketCap":12927967000},{"date":"2025-10-24","current":-37.571928,"twenty":-44.331016,"median":-41.888099,"eighty":-40.263942,"marketCap":11774394560},{"date":"2025-10-31","current":-34.030535,"twenty":-44.258383,"median":-41.766832,"eighty":-39.846145,"marketCap":10680489660},{"date":"2025-11-07","current":-37.063837,"twenty":-44.143742,"median":-41.612383,"eighty":-39.421071,"marketCap":11625225710},{"date":"2025-11-14","current":-37.306884,"twenty":-44.026925,"median":-41.504614,"eighty":-38.171485,"marketCap":11734616200},{"date":"2025-11-21","current":-32.263354,"twenty":-43.773799,"median":-41.293984,"eighty":-37.626872,"marketCap":10143481800},{"date":"2025-11-28","current":-33.407237,"twenty":-43.416049,"median":-41.25873,"eighty":-37.278832,"marketCap":10541265400},{"date":"2025-12-05","current":-32.531883,"twenty":-43.110759,"median":-40.854935,"eighty":-36.232015,"marketCap":10282706060},{"date":"2025-12-12","current":-33.445348,"twenty":-43.033782,"median":-40.504976,"eighty":-34.804627,"marketCap":10590988350},{"date":"2025-12-19","current":-31.455565,"twenty":-42.962519,"median":-40.253447,"eighty":-33.697999,"marketCap":9984368360},{"date":"2025-12-24","current":-31.920084,"twenty":-42.892338,"median":-39.907071,"eighty":-33.445348,"marketCap":10163370980},{"date":"2026-01-02","current":-31.421623,"twenty":-42.818917,"median":-39.811672,"eighty":-33.24713,"marketCap":10044035900},{"date":"2026-01-09","current":-34.757237,"twenty":-42.712093,"median":-39.628079,"eighty":-33.303022,"marketCap":11137940800},{"date":"2026-01-16","current":-34.953981,"twenty":-42.570843,"median":-39.220132,"eighty":-33.387129,"marketCap":11237386700},{"date":"2026-01-23","current":-34.708884,"twenty":-42.534258,"median":-38.04671,"eighty":-33.234922,"marketCap":11147885390},{"date":"2026-01-30","current":-41.208386,"twenty":-42.402729,"median":-37.93488,"eighty":-33.285275,"marketCap":13295916830},{"date":"2026-02-06","current":-38.552413,"twenty":-42.362692,"median":-38.04671,"eighty":-33.303022,"marketCap":12470515860},{"date":"2026-02-13","current":-37.506904,"twenty":-42.335079,"median":-38.011119,"eighty":-33.387129,"marketCap":12202011930},{"date":"2026-02-20","current":-39.795685,"twenty":-42.275235,"median":-38.202679,"eighty":-33.413439,"marketCap":12927967000},{"date":"2026-02-27","current":-37.9711,"twenty":-42.061223,"median":-38.358648,"eighty":-33.438876,"marketCap":12470515860},{"date":"2026-03-06","current":-32.876582,"twenty":-42.035836,"median":-37.973315,"eighty":-33.326804,"marketCap":10710323430},{"date":"2026-03-13","current":-37.800338,"twenty":-41.938243,"median":-37.9711,"eighty":-33.411645,"marketCap":12371069960},{"date":"2026-03-20","current":-39.652105,"twenty":-41.914066,"median":-38.162788,"eighty":-33.431073,"marketCap":12927967000},{"date":"2026-03-27","current":-45.563334,"twenty":-41.938243,"median":-38.422097,"eighty":-33.438876,"marketCap":14817439100},{"date":"2026-04-02","current":-73.055706,"twenty":-42.061577,"median":-38.676054,"eighty":-33.441386,"marketCap":17572695150},{"date":"2026-04-10","current":-74.98239,"twenty":-42.364587,"median":-38.815397,"eighty":-33.443763,"marketCap":18175244000},{"date":"2026-04-17","current":-69.940613,"twenty":-42.73421,"median":-39.081216,"eighty":-33.482556,"marketCap":16960268450},{"date":"2026-04-24","current":-67.940785,"twenty":-43.090538,"median":-39.261059,"eighty":-33.558052,"marketCap":16476253800},{"date":"2026-04-30","current":-65.13036,"twenty":-44.026925,"median":-39.582143,"eighty":-33.605745,"marketCap":15804560000},{"date":"2026-05-08","current":-55.847576,"twenty":-44.547984,"median":-39.760016,"eighty":-33.640661,"marketCap":16030679080},{"date":"2026-05-15","current":-43.849045,"twenty":-45.37348,"median":-39.795589,"eighty":-33.697999,"marketCap":12619684710},{"date":"2026-05-22","current":-44.434352,"twenty":-44.931837,"median":-39.87359,"eighty":-33.778461,"marketCap":12758908970},{"date":"2026-05-29","current":-42.313126,"twenty":-44.693978,"median":-39.965338,"eighty":-33.850015,"marketCap":12192067340},{"date":"2026-06-05","current":-38.943344,"twenty":-44.633844,"median":-39.952945,"eighty":-33.989804,"marketCap":11237386700},{"date":"2026-06-12","current":-37.176407,"twenty":-44.416359,"median":-39.831455,"eighty":-34.116239,"marketCap":10720268020},{"date":"2026-06-18","current":-37.166904,"twenty":-44.344385,"median":-39.795685,"eighty":-34.459057,"marketCap":10740157200},{"date":"2026-06-26","current":-34.282345,"twenty":-44.322103,"median":-39.774315,"eighty":-34.282345,"marketCap":9861055444},{"date":"2026-07-03","current":-36.446991,"twenty":-44.194662,"median":-39.640092,"eighty":-34.070689,"marketCap":10491542450},{"date":"2026-07-10","current":-34.534018,"twenty":-44.124681,"median":-39.536207,"eighty":-34.070689,"marketCap":9928678656},{"date":"2026-07-17","current":-44.462046,"twenty":-44.326559,"median":-39.640092,"eighty":-34.242022,"marketCap":12828521100},{"date":"2026-07-24","current":-43.03924,"twenty":-44.356568,"median":-39.788614,"eighty":-34.393423,"marketCap":12420792910},{"date":"2026-07-31","current":-36.732388,"twenty":-44.331016,"median":-39.652105,"eighty":-34.443911,"marketCap":10620822120},{"date":"2026-08-07","current":-44.144483,"twenty":-44.255348,"median":-39.774315,"eighty":-34.478204,"marketCap":12788742740},{"date":"2026-08-14","current":-50.259709,"twenty":-44.44543,"median":-39.795685,"eighty":-34.516798,"marketCap":14578768940},{"date":"2026-08-21","current":-48.712147,"twenty":-45.096211,"median":-39.845109,"eighty":-34.555887,"marketCap":14161096160},{"date":"2026-08-28","current":-49.214108,"twenty":-45.572671,"median":-39.940552,"eighty":-34.653517,"marketCap":14310265010},{"date":"2026-09-04","current":-40.091985,"twenty":-45.572671,"median":-40.024301,"eighty":-34.737896,"marketCap":12487782400},{"date":"2026-09-09","current":-39.527571,"twenty":-45.565149,"median":-39.965338,"eighty":-34.758603,"marketCap":12331685120}],"updateTime":1789030062036},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09887\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2650318595","title":"Nanjing Leads Biolabs Co Ltd: Actively Advancing Relevant Pre-launch Commercialization Preparations","url":"https://stock-news.laohu8.com/highlight/detail?id=2650318595","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650318595?lang=en_us&edition=fundamental","pubTime":"2026-07-10 16:55","pubTimestamp":1783673703,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260710:nFWN43C013:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","HK0000252160.HKD","HK0000252152.HKD","09887","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650185616","title":"Priority Review Granted to Pd-l1/4-1bb Bispecific Antibody Opamtistomig, Accelerating Commercialization and Addressing Unmet Need in Ep-nec","url":"https://stock-news.laohu8.com/highlight/detail?id=2650185616","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650185616?lang=en_us&edition=fundamental","pubTime":"2026-07-10 16:55","pubTimestamp":1783673703,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260710:nFWN43C013:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HK0000252152.HKD","09887","HK0000500386.USD","BK1161","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650907770","title":"Nanjing Leads Biolabs' Cancer Drug Included in China Regulator's Priority Review List","url":"https://stock-news.laohu8.com/highlight/detail?id=2650907770","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650907770?lang=en_us&edition=fundamental","pubTime":"2026-07-10 15:08","pubTimestamp":1783667303,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs'  biologics license application for LBL-024 was approved for inclusion in priority review and approval procedure by China's National Medical Products Administration.The drug has been developed as monotherapy for the treatment of advanced extrapulmonary neuroendocrine carcinoma, according to a Friday Hong Kong bourse filing.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HK0000252152.HKD","BK1161","HK0000252160.HKD","HK0000500386.USD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114500368","title":"LEADS BIOLABS-B's Novel Cancer Therapy LBL-024 Granted Priority Review in China for Advanced Neuroendocrine Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1114500368","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114500368?lang=en_us&edition=fundamental","pubTime":"2026-07-10 12:34","pubTimestamp":1783658060,"startTime":"0","endTime":"0","summary":"The biologics license application for LEADS BIOLABS-B's (ASX: 09887) investigational drug, VELIXIN™ (the PD-L1/4-1BB bispecific antibody oplitelimab, LBL-024), as a monotherapy for advanced...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PD","09887","BK4023","HK0000252152.HKD","HK0000252160.HKD","LU1169590202.USD","LU1169589451.USD","HK0000500386.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650901310","title":"Nanjing Leads Biolabs Says China Regulator Puts Lbl-024 Ep-nec Filing in Priority Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2650901310","media":"Reuters","labels":["shareholding","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650901310?lang=en_us&edition=fundamental","pubTime":"2026-07-10 12:28","pubTimestamp":1783657691,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs says China regulator puts LBL-024 EP-NEC filing in priority reviewNanjing Leads Biolabs’ China BLA for LBL-024 (opamtistomig) in advanced EP-NEC entered NMPA-CDE priority review.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260710:nNDL8LMSg9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","09887","HK0000500386.USD","BK1161","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189242408","title":"Leads Biolabs Converts 44.39 Million Unlisted Shares to H Shares, Lifting Outstanding H Shares to 197.67 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1189242408","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189242408?lang=en_us&edition=fundamental","pubTime":"2026-07-02 17:25","pubTimestamp":1782984351,"startTime":"0","endTime":"0","summary":"On 02 July 2026, Nanjing Leads Biolabs Co., Ltd. filed its Monthly Return for the period ended 30 June 2026 with Hong Kong Exchanges and Clearing Limited, detailing a sizeable realignment of its...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183498438","title":"LEADS BIOLABS-B Awards 2.2547 Million Shares Under H-Share Incentive Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=1183498438","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183498438?lang=en_us&edition=fundamental","pubTime":"2026-07-01 20:20","pubTimestamp":1782908424,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) has announced the granting of a total of 2.2547 million share awards under its H-share incentive scheme.The awards were granted to 149 recipients on July 1, 2026, and are subject to acceptance by the grantees to become effective.","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","09887","HK0000500386.USD","BK1161","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648051015","title":"Nanjing Leads Biolabs Grants 2,254,691 H-share Awards Under Employee Incentive Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=2648051015","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648051015?lang=en_us&edition=fundamental","pubTime":"2026-07-01 19:45","pubTimestamp":1782906351,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs grants 2,254,691 H-share awards under employee incentive schemeNanjing Leads Biolabs granted 2,254,691 share Awards under its H Share Award Scheme, covering 149 employees.Executi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nNDL8wPBMC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","HK0000252160.HKD","HK0000500386.USD","09887","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647575581","title":"This Nanjing Leads Biolabs Insider Reduced Their Stake By 40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2647575581","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647575581?lang=en_us&edition=fundamental","pubTime":"2026-06-30 09:44","pubTimestamp":1782783864,"startTime":"0","endTime":"0","summary":"From what we can see, insiders were net sellers in Nanjing Leads Biolabs Co., Ltd.'s ( HKG:9887 ) during the past 12...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9887/nanjing-leads-biolabs-shares/news/this-nanjing-leads-biolabs-insider-reduced-their-stake-by-40","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9887/nanjing-leads-biolabs-shares/news/this-nanjing-leads-biolabs-insider-reduced-their-stake-by-40","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","HK0000252160.HKD","HK0000500386.USD","09887","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119804571","title":"Assessing LEADS BIOLABS-B After a 50% Price Drop: H-Share Full Circulation, Early Shareholder Unlock, and Custody Movements","url":"https://stock-news.laohu8.com/highlight/detail?id=1119804571","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119804571?lang=en_us&edition=fundamental","pubTime":"2026-06-26 09:59","pubTimestamp":1782439157,"startTime":"0","endTime":"0","summary":"Since last September, the Hong Kong stock market's innovative drug sector has shifted from its previous bull market state, entering a volatile downtrend, with a particularly persistent decline...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","HK0000500386.USD","BK1161","HK0000252160.HKD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107543120","title":"New Energy System Blueprint and Rural EV Initiative Unveiled as Key Stocks Report Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=1107543120","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107543120?lang=en_us&edition=fundamental","pubTime":"2026-06-26 07:26","pubTimestamp":1782429979,"startTime":"0","endTime":"0","summary":"Two major national plans have been announced, focusing on the development of a new energy system by 2030 and a new round of rural new energy vehicle promotion. Key Developments The National...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1113","VXUS","BK1589","02616","BK1615","HK0000165453.HKD","03998","BK1502","02696","BK1613","HK0000252152.HKD","HK0000306701.USD","BK1109","BK1161","BK1512","HK0000320264.USD","LU1808992512.USD","80020","159945","BK1574","BK4585","HK0000306685.HKD","09887","09879","HK0000500386.USD","BK4588","HK0000320223.HKD","00020","BK1500","LU1675838814.USD","BK1227","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646874382","title":"Leads Biolabs Announces Partner Oblenio Bio’s $62 Million Oversubscribed Series B Financing to Advance Tri-specific T-cell Engager Lbl‑051 for Autoimmune Diseases into Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2646874382","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646874382?lang=en_us&edition=fundamental","pubTime":"2026-06-25 18:38","pubTimestamp":1782383880,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nTUA2BPFC5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HK0000252152.HKD","HK0000500386.USD","HK0000252160.HKD","09887","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646743858","title":"Nanjing Leads Biolabs Co - Series B Round Led by Pfizer Ventures with Deep Track Capital, Gv, and Aditum Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=2646743858","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646743858?lang=en_us&edition=fundamental","pubTime":"2026-06-25 18:38","pubTimestamp":1782383880,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nTUA2BPFC5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0868494617.USD","SG9999003800.SGD","BK1161","IE00BLSP4239.USD","LU0122379950.USD","LU1023059063.AUD","SGXZ57979304.SGD","SG9999001176.USD","BK4550","BK4534","LU1894683348.USD","BK4599","SG9999002224.SGD","BK4568","IE000M9KFDE8.USD","BK4007","LU0306806265.USD","PFE","HK0000252160.HKD","IE00BBT3K403.USD","LU0289739699.SGD","LU0225284248.USD","LU0306807586.USD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","LU0985481810.HKD","LU1057294990.SGD","IE00B3T34201.USD","LU0170899867.USD","LU1066051498.USD","SG9999001176.SGD","LU0456855351.SGD","LU0225771236.USD","LU0058720904.USD","09887","LU0321505868.SGD","LU1894683264.USD","SG9999013999.USD","BK4533","BK4581","SG9999002232.USD","BK4588","LU1883839398.USD","LU2596442595.SGD","BK4592","LU0321505439.SGD","SG9999011175.SGD","HK0000500386.USD","IE00BLSP4452.SGD","LU0234572021.USD","HK0000252152.HKD","IE0002270589.USD","LU1066053197.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646879406","title":"Nanjing Leads Biolabs Says Partner Oblenio Moves Lbl-051 Toward Clinical Trial Start After US$62 Million Series B Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2646879406","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646879406?lang=en_us&edition=fundamental","pubTime":"2026-06-25 18:01","pubTimestamp":1782381702,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs says partner Oblenio moves LBL-051 toward clinical trial start after US$62 million Series B financingNanjing Leads Biolabs’ partner Oblenio Bio closed an oversubscribed USD 62 mi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nNDL4gVVJq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","BK1161","HK0000252160.HKD","HK0000252152.HKD","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113955695","title":"Leads Biolabs Completes H-Share Full Circulation, Free-Float Rises to 99.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=1113955695","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113955695?lang=en_us&edition=fundamental","pubTime":"2026-06-05 20:04","pubTimestamp":1780661065,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) announced the successful completion of its H-share full circulation programme, converting 44.39 million previously unlisted domestic shares into H...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641117625","title":"Nanjing Leads Biolabs converts 44,391,598 unlisted shares into H shares for HKEX listing","url":"https://stock-news.laohu8.com/highlight/detail?id=2641117625","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641117625?lang=en_us&edition=fundamental","pubTime":"2026-06-05 19:24","pubTimestamp":1780658645,"startTime":"0","endTime":"0","summary":"Converted 44,391,598 unlisted shares into H shares; conversion completed June 4, 2026.Converted H shares began trading in Hong Kong at 9:00 a.m. on June 5, 2026.H shares rose to 197,670,289 from 153,278,691; stake increased to 99.39% from 77.07%.Unlisted shares fell to 1,221,511 from 45,613,109; stake dropped to 0.61% from 22.93%.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on June 05, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nNDL3LzCGB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000500386.USD","BK1161","HK0000252160.HKD","09887","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198050083","title":"LEADS BIOLABS-B Records HK$1.486 Billion in Deposited Shares as Major Holder Transfers 25.85 Million Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1198050083","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198050083?lang=en_us&edition=fundamental","pubTime":"2026-06-05 08:26","pubTimestamp":1780619193,"startTime":"0","endTime":"0","summary":"According to the latest data from the Hong Kong Stock Exchange, a significant position change occurred for LEADS BIOLABS-B (09887) on June 4th. The total market value of shares deposited reached...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","BK1161","HK0000252160.HKD","HK0000252152.HKD","HK0000500386.USD","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638651382","title":"Nanjing Leads Biolabs says LBL-024 Phase II first-line NSCLC data wins oral slot at 2026 WCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2638651382","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638651382?lang=en_us&edition=fundamental","pubTime":"2026-05-28 12:01","pubTimestamp":1779940868,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs said Phase II results for Opamtistomig  in first-line NSCLC will be presented at the 2026 WCLC on Sept. 12-15.The study tested Opamtistomig with chemotherapy, showing strong tumor responses that improved with longer follow-up across key patient subgroups.Safety remained consistent with earlier disclosures, supporting the group’s strategy to position the PD-L1/4-1BB bispecific as a broader oncology platform asset.The company cited more than 600 patients treated across programs, with escalating doses in trials without dose-limiting toxicity reported to date.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the regul","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDL104zH9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000500386.USD","HK0000252160.HKD","09887","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158348933","title":"Leads Biolabs to Spend up to US$50 Million on Trustee-Led H-Share Purchases for Employee Award Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=1158348933","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158348933?lang=en_us&edition=fundamental","pubTime":"2026-05-20 19:22","pubTimestamp":1779276169,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) has authorised the trustee of its H Share Award Scheme to buy additional H shares on the open market for an aggregate consideration of up to US$50.00...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153977350","title":"LEADS BIOLABS-B (09887) Authorizes Trustee to Acquire Up to $50 Million Worth of H Shares Under Incentive Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1153977350","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153977350?lang=en_us&edition=fundamental","pubTime":"2026-05-20 19:20","pubTimestamp":1779276036,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) has announced that the company has instructed the trustee to utilize plan funds, with a total maximum amount of $50 million, to acquire additional H shares through open market...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000500386.USD","09887","HK0000252160.HKD","HK0000252152.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":4,"totalSize":133,"code":"91000000","status":"200"}]}}